About 34 results found for searched term "GSK-3 inhibitor 3" (0.075 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3054 | TDZD-8 | GSK-3 |
| GSK-3β Inhibitor I; NP 01139 | ||
| TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC. | ||
| M43379 | GSK-3 inhibitor 3 | GSK-3 |
| GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of GSK-3, with IC50s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. | ||
| M43380 | GSK-3β inhibitor 13 | GSK-3 |
| GSK-3β inhibitor 13 is an orally active and potent GSK-3β inhibitor with blood-brain permeability. | ||
| M49758 | GSK-3β inhibitor 3 | GSK-3 |
| GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC50 of 6.6 μM. | ||
| M1789 | GSK690693 | Akt |
| GSK-690693 | ||
| GSK690693 is a potent Akt inhibitor (Akt1 IC50 = 2 nM, Akt2 IC50 = 13 nM, Akt3 IC50 = 9 nM) which also inhibited the phosphorylation of the downstream target GSK3b in cells. | ||
| M2061 | SB 216763 | GSK-3 |
| SB 216763 is a potent and selective, cell permeable glycogen synthase kinase-3 (GSK-3) inhibitor with an IC50 value of 34 nM for GSK-3α. | ||
| M2171 | GSK923295 | Kinesin |
| GSK923295 is an allosteric inhibitor of CENP-E with Ki value of 3.2 nM. | ||
| M2304 | TWS119 | GSK-3 |
| TWS119 is a GSK-3β inhibitor with IC50 of 30 nM. | ||
| M2305 | CHIR-98014 | GSK-3 |
| CHIR-98014 is a potent and selective GSK-3 inhibitor for GSK-3ɑ and GSK-3β with IC50 of 0.65 nM and 0.58 nM, respectively. | ||
| M2405 | AR-A014418 | GSK-3 |
| GSK-3β Inhibitor VIII | ||
| AR-A014418 is an ATP-competitive, and selective GSK3β inhibitor with IC50 and Ki of 104 nM and 38 nM, without significant inhibition on 26 other kinases tested. | ||
| M2417 | AZD1080 | GSK-3 |
| AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with Ki of 6.9 nM and 31 nM, respectively. | ||
| M2731 | GSK-J4 hydrochloride | Histone demethylase |
| GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC50 of 9 μM. GSK J4 hydrochloride is a cell permeable procompound of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM and inactive against a panel of demethylases of the JMJ family. | ||
| M2826 | LY2090314 | GSK-3 |
| LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. Phase 1/2. | ||
| M3442 | SB415286 | GSK-3 |
| SB415286 is a potent GSK3α inhibitor with IC50/Ki of 78 nM/31 nM with equally effective inhibition of GSK-3β. | ||
| M3484 | Dolutegravir | Integrase |
| GSK1349572 | ||
| Dolutegravir (GSK1349572) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. | ||
| M3691 | IM-12 | GSK-3 |
| IM-12 is a potent and selective GSK-3β inhibitor with IC50 of 53 nM, which also enhances canonical Wnt signalling. | ||
| M5269 | GSK180736A | ROCK |
| GSK180736 | ||
| GSK180736A, developed as a Rho-associated, coiled-coil-containing protein kinase inhibitor, binds to GRK2(G protein-coupled receptor kinase 2) with logIC50 pf -6.6 (logIC50 -4.0 for GRK5 and >-3 for GRK1); ≥400-fold selective for GRK2 over both GRK1 and GRK5. | ||
| M5308 | Afuresertib | Akt |
| GSK2110183; LAE002 | ||
| Afuresertib (GSK2110183; LAE002) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. | ||
| M5325 | GSK 650394 | SGK |
| GSK650394 is a serum- and glucocorticoid-regulated kinase-1 inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2, respectively. | ||
| M6594 | CHIR 99021 trihydrochloride | GSK-3 |
| Laduviglusib trihydrochloride; CT99021 trihydrochloride | ||
| Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. | ||
| M6771 | GSK2837808A | LDH |
| GSK 2837808A | ||
| GSK2837808A is a potent, selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively. | ||
| M6772 | GSK 319347A | IκB/IKK |
| GSK319347A | ||
| GSK319347A is a dual inhibitor of TBK1 and IKKε with IC50s of 93 nM and 469 nM, respectively. | ||
| M7627 | BIO | GSK-3 |
| 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime6BIO; GSK 3 IX; GSK 3 Inhibitor IX; MLS 2052 | ||
| BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific GSK-3 inhibitor, the IC50 acting on GSK-3α/β in cell-free assays is 5 nM, which is more than 16 times more selective than ACTing on CDK5. It is also a pan-JAK inhibitor with an IC50 value of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells. | ||
| M9074 | GSK872 | RIPK |
| GSK-872 | ||
| GSK872 is a receptor interacting protein kinase-3 (RIP3) inhibitor, which inhibits kinase activity with an IC50 of 1.3 nM. | ||
| M9146 | GSK1324726A | Epigenetic Reader Domain |
| I-BET726 | ||
| GSK1324726A (I-BET726) is a highly selective inhibitor of BET family proteins with IC50 of 41 nM, 31 nM, and 22 nM for BRD2, BRD3, and BRD4, respectively. | ||
| M9871 | GSK2643943A | Deubiquitinase |
| GSK2643943A is a deubiquitylating enzyme (DUB) inhibitor targeting USP20/Ub-Rho with an IC50 of 160 nM. GSK2643943A has anti-tumor efficacy and can be used for the research of oral squamous cell carcinoma (OSCC). | ||
| M10108 | Indirubin-3'-monoxime | GSK-3 |
| I3MO | ||
| Indirubin-3'-monoxime is a potent GSK-3β inhibitor with IC50 of 22 nM, and inhibits Cdk5/p35, Cdk1/cyclin-B and Cdk2/cyclin-E with IC50s of 100, 180, 250 nM. | ||
| M10531 | BRD3731 | GSK-3 |
| BRD3731 is a selective GSK3β inhibitor, with IC50s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. | ||
| M10637 | GSK3368715 2HCl | PRMTs |
| EPZ019997 2HCl | ||
| GSK3368715 2HCl is a novel potent, orally active, reversible type I protein arginine methyltransferases (PRMTs) inhibitor, with IC50 values of 3.1 nM, 48 nM, 1148 nM, 5.7 nM and 1.7 nM for PRMT1, PRMT3, PRMT4, PRMT6, PRMT8, respectively. | ||
| M10933 | GSK3179106 | RET |
| GSK3179106 is an orally active, selective RET kinase inhibitor for human and rat RET IC50 0.4 nM and 0.2 nM, respectively. GSK3179106 has the potential for use in irritable bowel syndrome (IBS) by reducing post-inflammatory and stress-induced visceral hypersensitivity reactions. | ||
| M11184 | GSK3145095 | RIPK |
| GSK3145095 is a potent inhibitor of the oral activity RIP1 kinase with an IC50 of 6.3 nM with potential antitumor and immunomodulatory activity. | ||
| M13358 | GSK-843 | Necroptosis |
| GSK'843 | ||
| GSK-843 is a potent receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 8.6 nM, and inhibits kinase activity with an IC50 of 6.5 nM. | ||
| M13359 | GSK963 | RIPK |
| GSK'963 | ||
| GSK963 is a chiral small-molecule inhibitor of RIP1 kinase (RIPK1) with an IC50 value of 29 nM. GSK963 has strong and selective inhibitory effect on the necrosis of mouse and human cells in vitro. | ||
| M13394 | GSK2593074A | RIPK |
| GSK'074 | ||
| GSK2593074A is a necroptosis inhibitor that inhibits RIP1 and 3. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
